What is the clinical evidence from this study?

Study design: Cohort. Population: Coronary artery bypass grafting (CABG) (n=258). Intervention: Ticagrelor vs. Clopidogrel. Primary outcome: Day-3 C-reactive protein (CRP) (MD -20.96, 95% CI -27.74 to -14.18, p=<0.001).

What does this research mean for the field?

In statin-treated patients undergoing on-pump CABG, ticagrelor is associated with lower early post-operative systemic inflammation and a higher CD4/CD8 ratio compared with clopidogrel, largely independent of platelet inhibition. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

Determine whether ticagrelor attenuates early postoperative systemic inflammation and improves the CD4/CD8 ratio compared with clopidogrel in patients undergoing on-pump CABG.

September 25, 2026Discovery MedicineOpen Access

Ticagrelor linked to ~21 mg/L lower day-3 CRP and higher CD4/CD8 ratio vs clopidogrel post-CABG.

Q: What are the key findings of this study?

Ticagrelor was associated with lower day-3 C-reactive protein (adjusted difference -20.96 mg/L) and a higher CD4/CD8 ratio compared to clopidogrel in statin-treated patients after on-pump CABG.

Q: What does this research mean for the field?

In statin-treated patients undergoing on-pump CABG, ticagrelor is associated with lower early post-operative systemic inflammation and a higher CD4/CD8 ratio compared with clopidogrel, largely independent of platelet inhibition. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Q: What question did this study set out to answer?

Determine whether ticagrelor attenuates early postoperative systemic inflammation and improves the CD4/CD8 ratio compared with clopidogrel in patients undergoing on-pump CABG.

View Full Paper

Ask AI

Bookmark

Why the study?

Does ticagrelor reduce early post-CABG inflammation and improve the CD4/CD8 ratio compared to clopidogrel in statin-treated patients undergoing on-pump CABG?

Population

258 patients undergoing elective isolated on-pump CABG under guideline-directed statin therapy, of whom 179…

Comparison

Ticagrelor vs Clopidogrel

Design

Cohort

Follow-up

3 days

Key result

Ticagrelor was associated with lower day-3 C-reactive protein (adjusted difference -20.96 mg/L) and a higher CD4/CD8 ratio compared to clopidogrel in statin-treated patients after on-pump CABG.

Authors

RYRuijun Yuan BZBoyao Zhang KZKeng Zhong

Discussion

Member takes

Overview

Residual LDL-C stratification may identify post-CABG patients with heightened inflammatory risk; leaves open whether ticagrelor attenuates T-cell depression in this subgroup.

Key Points

Determine whether ticagrelor attenuates early postoperative systemic inflammation and improves the CD4/CD8 ratio compared with clopidogrel in patients undergoing on-pump CABG.
Single-center retrospective 1:1 propensity-score-matched cohort study evaluating 258 patients (129 pairs) undergoing elective isolated on-pump CABG under statin therapy.
Assessed co-primary outcomes of day-3 C-reactive protein (CRP) and CD4/CD8 ratio via ANCOVA adjusted for baseline values, stratified by residual LDL-C (≥1.4 mmol/L).
Exploratory statistical decomposition was conducted to evaluate the proportion of treatment differences shared with ADP-induced platelet inhibition.
Ticagrelor was associated with lower day-3 CRP (adjusted difference –20.96 mg/L, 95% CI –27.74 to –14.18, ~12% relative reduction; p < 0.001).
Ticagrelor was associated with a higher day-3 CD4/CD8 ratio (adjusted difference +0.117, 95% CI 0.058 to 0.175; p < 0.001), with no significant effect modification by residual LDL-C.
Exploratory decomposition showed platelet inhibition statistically accounted for 34.5% of the CRP reduction and 41.2% of the CD4/CD8 ratio difference, leaving the majority of the effect unexplained by platelet reactivity.

Study Design

Type

Cohort (n=258)

Multicenter

Structured PICO

Does ticagrelor reduce early post-CABG inflammation and improve the CD4/CD8 ratio compared to clopidogrel in statin-treated patients undergoing on-pump CABG?

Population

258 statin-treated patients undergoing elective isolated on-pump CABG, matched by propensity score, evaluated for early postoperative inflammation and immune response on day 3.

Exposure

Ticagrelor

Comparator

Clopidogrel

Outcome

Co-primary outcomes of day-3 C-reactive protein (CRP) and CD4/CD8 ratiosurrogate

Main Result

Mean Difference: -20.96 (95% CI -27.74–-14.18)

Absolute Event Rate: 146.88% vs 167.19%

p-value: p=<0.001

In statin-treated patients undergoing on-pump CABG, ticagrelor is associated with lower early postoperative inflammation and a higher CD4/CD8 ratio compared to clopidogrel.

Limitations

Single-center retrospective cohort design.
Complete-case cohort conditional on survival to and sampling on day 3.
Exploratory decomposition of platelet reactivity is cross-sectional and cannot be interpreted as causal mediation.
Limited power for testing effect modification by residual LDL-C.
Single-center retrospective cohort design
Exploratory decomposition cannot be interpreted as mediation
Hypothesis-generating findings warranting confirmation in a randomized trial

Cite This Study

Yuan et al. (2026) conducted a cohort in Coronary artery bypass grafting (CABG) (n=258). Ticagrelor vs. Clopidogrel was evaluated on Day-3 C-reactive protein (CRP) (MD -20.96, 95% CI -27.74 to -14.18, p=<0.001). Ticagrelor was associated with lower day-3 C-reactive protein (adjusted difference -20.96 mg/L) and a higher CD4/CD8 ratio compared to clopidogrel in statin-treated patients after on-pump CABG.

synapsesocial.com/papers/6ab60fbe406bf401c1468976 https://doi.org/10.24976/discov.med.202638212.218

View Full Paper

Ask AI

Bookmark

September 25, 2026Discovery MedicineOpen Access

Ticagrelor linked to ~21 mg/L lower day-3 CRP and higher CD4/CD8 ratio vs clopidogrel post-CABG.

View Full Paper

Ask AI

Bookmark

Why the study?

Does ticagrelor reduce early post-CABG inflammation and improve the CD4/CD8 ratio compared to clopidogrel in statin-treated patients undergoing on-pump CABG?

Population

258 patients undergoing elective isolated on-pump CABG under guideline-directed statin therapy, of whom 179…

Comparison

Ticagrelor vs Clopidogrel

Design

Cohort

Follow-up

3 days

Key result

Ticagrelor was associated with lower day-3 C-reactive protein (adjusted difference -20.96 mg/L) and a higher CD4/CD8 ratio compared to clopidogrel in statin-treated patients after on-pump CABG.

Authors

RYRuijun Yuan BZBoyao Zhang KZKeng Zhong

Discussion

Member takes

Overview

Residual LDL-C stratification may identify post-CABG patients with heightened inflammatory risk; leaves open whether ticagrelor attenuates T-cell depression in this subgroup.

Key Points

Determine whether ticagrelor attenuates early postoperative systemic inflammation and improves the CD4/CD8 ratio compared with clopidogrel in patients undergoing on-pump CABG.
Single-center retrospective 1:1 propensity-score-matched cohort study evaluating 258 patients (129 pairs) undergoing elective isolated on-pump CABG under statin therapy.
Assessed co-primary outcomes of day-3 C-reactive protein (CRP) and CD4/CD8 ratio via ANCOVA adjusted for baseline values, stratified by residual LDL-C (≥1.4 mmol/L).
Exploratory statistical decomposition was conducted to evaluate the proportion of treatment differences shared with ADP-induced platelet inhibition.
Ticagrelor was associated with lower day-3 CRP (adjusted difference –20.96 mg/L, 95% CI –27.74 to –14.18, ~12% relative reduction; p < 0.001).
Ticagrelor was associated with a higher day-3 CD4/CD8 ratio (adjusted difference +0.117, 95% CI 0.058 to 0.175; p < 0.001), with no significant effect modification by residual LDL-C.
Exploratory decomposition showed platelet inhibition statistically accounted for 34.5% of the CRP reduction and 41.2% of the CD4/CD8 ratio difference, leaving the majority of the effect unexplained by platelet reactivity.

Study Design

Type

Cohort (n=258)

Multicenter

Structured PICO

Does ticagrelor reduce early post-CABG inflammation and improve the CD4/CD8 ratio compared to clopidogrel in statin-treated patients undergoing on-pump CABG?

Population

258 statin-treated patients undergoing elective isolated on-pump CABG, matched by propensity score, evaluated for early postoperative inflammation and immune response on day 3.

Exposure

Ticagrelor

Comparator

Clopidogrel

Outcome

Co-primary outcomes of day-3 C-reactive protein (CRP) and CD4/CD8 ratiosurrogate

Main Result

Mean Difference: -20.96 (95% CI -27.74–-14.18)

Absolute Event Rate: 146.88% vs 167.19%

p-value: p=<0.001

In statin-treated patients undergoing on-pump CABG, ticagrelor is associated with lower early postoperative inflammation and a higher CD4/CD8 ratio compared to clopidogrel.

Limitations

Single-center retrospective cohort design.
Complete-case cohort conditional on survival to and sampling on day 3.
Exploratory decomposition of platelet reactivity is cross-sectional and cannot be interpreted as causal mediation.
Limited power for testing effect modification by residual LDL-C.
Single-center retrospective cohort design
Exploratory decomposition cannot be interpreted as mediation
Hypothesis-generating findings warranting confirmation in a randomized trial

Cite This Study

synapsesocial.com/papers/6ab60fbe406bf401c1468976 https://doi.org/10.24976/discov.med.202638212.218

View Full Paper

Ask AI

Bookmark